Dr. David Malebranche (@DMalebranche) talks injectable PrEP and HIV research.
Please See Two Clarifications From Dr. Malebranche:
1. In the video it is stated the HIV incidence rate in the Cabotegravir arm of HPTN 083 study was .038%. It's actually 0.38%.
2. Clarification on Studies: HPTN 083 is the study recently released and was with Cisgender MSM and Transgender Women. HPTN 084 is the study focused on Cisgender Women.
